Monopar Therapeutics MNPR Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's operating income?
- Monopar Therapeutics (MNPR) reported operating income of -$5.23M in Q1 2026.
- How has Monopar Therapeutics's operating income changed year-over-year?
- Monopar Therapeutics's operating income decreased by 62.2% year-over-year, from -$3.22M to -$5.23M.
- What is the long-term trend for Monopar Therapeutics's operating income?
- Over 4 years (2021 to 2025), Monopar Therapeutics's operating income has grown at a 16.3% compound annual growth rate (CAGR), from -$9.13M to -$16.7M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.